Bedaquiline (TMC-207)

Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

Publication: PLOS One

Author(s): A Gupta, S Juneja, V Babawale, N R Majidovich, N Ndjeka, P T M Nguyen, P Nargiza Nusratovna, D R Omanito, T T Pakasi, Y Terleeva, A Toktogonova, Y Waheed, Z Myint, Z Yanlin, S Sahu

1/2024

Tags: Advocacy, Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Policy, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid

Publication: PLOS Global Public Health

Author(s): Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun

10/2023

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824

The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis

Publication: Clinical Infectious Diseases

Author(s): Tasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, Erica Egizi, Catherine Berry, Matthew Dodd, Salah Foraida, Medea Gegia, Mengchun Li, Fuad Mirzayev, Hannah Morgan, Ilaria Motta, Linh Nguyen, Samuel Schumacher, Tim Schlub, Greg Fox

10/2023

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model

Publication: Antimicrobial Agents and Chemotherapy

Author(s): Si-Yang Li, Paul J. Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L. Nuermberger

3/2023

Tags: Bedaquiline (TMC-207), BPaL, Clinical Development, Drug Discovery, Linezolid, Preclinical Data, Preclinical Models, Pretomanid/PA-824

Stable compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field

Publication: International Journal of Tuberculosis and Lung Disease

Author(s): R Taneja, M C Nahata, J Scarim, P G Pande, A Scarim, G Hoddinott, C L Fourie, R K Jew, H S Schaaf, A J Garcia-Prats, A C Hesseling

3/2023

Tags: Bedaquiline (TMC-207), BENEFIT Kids, Childhood TB, TB Burden, TB Market, Underserved Populations

Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs

Publication: International Journal of Tuberculosis and Lung Disease

Author(s): Jaw-Tsai, S., Barry, R., Pande, P. G., Taneja, R., Yang, T.

1/2023

Tags: Bedaquiline (TMC-207)

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis

Publication: PLOS Global Public Health

Author(s): Aastha Gupta, Sandeep Juneja, Suvanand Sahu, Mohammed Yassin, Grania Brigden, Eliud Wandwalo, Saurabh Rane, Fuad Mirzayev, Matteo Zignol

11/2022

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Publication: New England Journal of Medicine

Author(s): Francesca Conradie, et al., for the ZeNix Trial Team

9/2022

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, XDR-TB

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis

Publication: Antimicrobial Agents and Chemotherapy

Author(s): Deepak Almeida, Paul J. Converse, Si-Yang Li, Anna M. Upton, Nader Fotouhi, and Eric L. Nuermberger

12/2021

Tags: Bedaquiline (TMC-207), Preclinical Data, Preclinical Models

Pretomanid with Bedaquiline and Linezolid for Drug Resistant TB: A Comparison of Prospective Cohorts

Author(s): S. Oelofse, A. Esmail, A. H. Diacon F. Conradie, O. Olayanju, N. Ngubane, P. Howell, D. Everitt, A. M. Crook, C. M. Mendel, G. H. Wills, M. Olugbosi, A. del Parigi, E. Sun, A. Calatroni, M. Spigelman, K. Dheda

4/2021

Tags: Bedaquiline (TMC-207), Linezolid, MDR-TB, Pretomanid/PA-824

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

Author(s): Jian Xu, Paul J. Converse, Anna M. Upton, Khisimuzi Mdluli, Nader Fotouhi, Eric L. Nuermberger

2/2021

Tags: Bedaquiline (TMC-207), M.tb. Biology, Preclinical Data, Preclinical Models

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Publication: The New England Journal of Medicine

Author(s): Francesca Conradie, M.B., B.Ch., Andreas H. Diacon, M.D., Nosipho Ngubane, M.B., B.Ch., Pauline Howell, M.B., B.Ch., Daniel Everitt, M.D., Angela M. Crook, Ph.D., Carl M. Mendel, M.D., Erica Egizi, M.P.H., et al., for the Nix-TB Trial Team*

3/2020

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, Trial Design, XDR-TB

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Publication: The Lancet Respiratory Medicine

Author(s): Conor D Tweed, Rodney Dawson, Divan A Burger, Almari Conradie, Angela M Crook, Carl M Mendel, Francesca Conradie, Andreas H Diacon, Nyanda E Ntinginya, Daniel E Everitt, Frederick Haraka, Mengchun Li, Christo H van Niekerk, Alphonse Okwera

11/2019

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Trial Results, MDR-TB, Moxifloxacin, NC-005, PaMZ, Pretomanid/PA-824, Trial Design

Daily Dosing for Bedaquiline in Patients with Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann

10/2019

Tags: Bedaquiline (TMC-207), BPaL

Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations

Publication: BMC Infectious Diseases

Author(s): Emily A. Kendall, Shelly Malhotra, Sarah Cook-Scalise, Claudia M. Denkinger, David W. Dowdy

9/2019

Tags: Bedaquiline (TMC-207), Moxifloxacin, Pyrazinamide, Regimen Change

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton, Mdluli, Fotouhi, Nuermberger EL

4/2019

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units

Publication: Bioorganic & Medicinal Chemistry Letters

Author(s): Peter Choi, Hamish Sutherland, Amy S.T.Tong, Adrian Blaser, Scott Franzblau, Christopher B.Cooper, Manisha U.Lotlikar, Anna M.Upton, Jerome Guillemont, Magali Motte, Laurence Queguiner, Koen Andries, Walter Van den Broeck, William A.Denny, Brian D.Palmer

10/2017

Tags: Bedaquiline (TMC-207), Drug Discovery, M.tb. Biology

Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

Publication: Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.

4/2015

Tags: Bedaquiline (TMC-207), BPaZ, Clinical Development, Clinical Trial Results, Clofazamine, NC-003, Pretomanid/PA-824, Pyrazinamide, TB-HIV

Evaluation of the Pharmacokinetic Interaction between Repeated Doses of Rifapentine or Rifampin and a Single Dose of Bedaquiline in Healthy Adult Subjects

Publication: Winter H, Egizi E, Erondu N, et. al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother. 2015 Feb;59(2):1219-24. doi: 10.1

12/2014

Tags: Bedaquiline (TMC-207), Clinical Development, Clinical Trial Results, Pharmacokinetics, Rifapentine

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Publication: Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504.